Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

I-Mab Tailors its Immunotherapy Products for China
I-Mab Tailors its Immunotherapy Products for China
Associated Company
I-Mab Biopharma I-Mab Biopharma

Immunotherapy returned to the public with a positive attitude because of the attention and recognition of the Nobel Prize for Medicine in 2018; its public perspective in China was deeply influenced by the WEI Zexi (魏则西) incident. Immunotherapy, as its name implies, is the treatment of cancer by activating the original ability of T cells and the immune system to fight against cancer cells.

Currently, the main therapies include immunological checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. CAR-T cell therapy can transform human T cells to recognize tumour antigens and stimulate the immune system to remove cancer cells. Relevant research has entered the commercial market and its effectiveness has been constantly excavated. 

As immunotherapy popularized and matures, I-Mab Biopharma (天境生物) thrives its business and moves closer to its IPO. I-Mab-Biopharma is a biopharmaceutical research and development company located in Shanghai, focusing on tumour treatment and autoimmune diseases. (Find more on the 2019 Technology Trends Report in China)

Founded in 2016, I-Mab is valued at around half a billion USD from its latest series C financing of USD 220 million in June 2018. I-Mab has entered several R&D collaborations with clinical research institutes for developing novel immunotherapy. The company is at the dawn of its IPO.

Other sizable and innovative Chinese startups are Shanghai Cell Therapy Group (上海细胞治疗集团  ) with USD 74 million and Jacobio Pharma (加科思 ) with USD 55 million total fundings. However, I-Mab is the biggest and the most immunotherapy focused company amongst them. The company's unique value proposition is its China tailored immunotherapy portfolio which will be commercialized after 2021. 

China is the second biggest immunotherapy contributor globally by the number of institutional initiative; however, the country's cancer problem is much more severe than what is provided as a solution. I-Mab wants to position itself within this landscape.

Enterprise Information

Tianjing Bio is a technology company specializing in the field of innovative biomedicine.
CATEGORIES: Healthcare
Last Funding Type
Series C
Number of Employees
50-100
Number of Funding Rounds
5
Total Funding Amount
470.00M

Enterprise Information

I-Mab Biopharma
Tianjing Bio is a technology company specializing in the field of innovative biomedicine.
CATEGORIES: Healthcare
Last Funding Type
Series C
Number of Employees
50-100
Number of Funding Rounds
5
Total Funding Amount
470.00M

Communicate Directly with the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Any Question

EqualOcean is a leading industrial tech media and investment research company that focuses on technological and industrial innovation in China.

We aim to assist Chinese entrepreneurial enterprises to break into the global market and provide overseas investors, VCs, and enterprises with a deeper understanding of China's business environment and to seize opportunities in China.

Join over 800,000 of your peers